{"organizations": [], "uuid": "15ed38f6f10ec2d4d9862a2e8fc1e0ab199932e8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-aslan-pharmaceuticals-buys-full-gl/brief-aslan-pharmaceuticals-buys-full-global-commercial-rights-for-varlitinib-idUSASB0BZJ0", "country": "US", "domain_rank": 408, "title": "BRIEF-Aslan Pharmaceuticals buys full global commercial rights for Varlitinib", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-03T10:04:00.000+02:00", "replies_count": 0, "uuid": "15ed38f6f10ec2d4d9862a2e8fc1e0ab199932e8"}, "author": "", "url": "https://www.reuters.com/article/brief-aslan-pharmaceuticals-buys-full-gl/brief-aslan-pharmaceuticals-buys-full-global-commercial-rights-for-varlitinib-idUSASB0BZJ0", "ord_in_thread": 0, "title": "BRIEF-Aslan Pharmaceuticals buys full global commercial rights for Varlitinib", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-aslan pharmaceuticals", "sentiment": "negative"}, {"name": "varlitinib reuters staff  jan", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "aslan pharmaceuticals ltd", "sentiment": "none"}, {"name": "aslan", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 3, 2018 / 8:05 AM / Updated an hour ago BRIEF-Aslan Pharmaceuticals buys full global commercial rights for Varlitinib Reuters Staff \nJan 3 (Reuters) - Aslan Pharmaceuticals Ltd: \n* ASLAN PHARMACEUTICALS ACQUIRES FULL GLOBAL COMMERCIAL RIGHTS FOR VARLITINIB FROM ARRAY BIOPHARMA \n* ARRAY BIOPHARMA INC HAS GRANTED ASLAN FULL GLOBAL RIGHTS TO DEVELOP, MANUFACTURE AND COMMERCIALISE VARLITINIB​ \n* ASLAN WILL MAKE AN UPFRONT PAYMENT OF $12 MILLION TO ARRAY ON SIGNATURE AND FURTHER PAYMENT OF UP TO $12 MILLION WITHIN NEXT 12 MONTHS​ \n* ASLAN WILL MAKE UPFRONT PAYMENT TOGETHER WITH UP TO US$30 MILLION OF DEVELOPMENT AND US$75 MILLION OF COMMERCIAL MILESTONES Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-03T10:04:00.000+02:00", "crawled": "2018-01-03T10:26:43.002+02:00", "highlightTitle": ""}